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Abstract
Study Design: Cost-effectiveness analysis.
Objectives: To determine the 7-year cost-effectiveness of cervical disc replacement (CDR) and anterior cervical discectomy and
fusion (ACDF).
Methods:We analyzed 7-year Short Form-36 Health Survey data collected from the Prestige Cervical Disc investigational device
exemption study (IDE). The SF-6D algorithm was used to convert this data into health state utilities. Costs were calculated from
the payer perspective, and quality adjusted life years (QALYs) were used to represent effectiveness. A Markov transition-state
model was used to evaluate the cost-effectiveness of single-level CDR versus ACDF, and a Monte Carlo simulation was
performed to assess the probabilistic sensitivity of the model.
Results: CDR generated a 7-year cost of $172989 compared to a 7-year cost of $143714 for ACDF. CDR generated 4.53
QALYs compared to 3.85 QALYs generated by ACDF. The cost-effectiveness ratio of CDR was $38247/QALY, while the cost-
effectiveness ratio of ACDF was $37325/QALY. The incremental cost-effectiveness ratio of CDR was $43522/QALY, under the
willingness to pay threshold of $50000/QALY. Our probabilistic sensitivity analysis demonstrated CDR would be chosen 56% of
the time based on 10000 simulations.
Conclusions: Single-level CDR and ACDF were both cost-effective strategies at 7 years for treating degenerative conditions of
the cervical spine. Both the Markov simulation and the Monte Carlo simulation demonstrate CDR to be the more cost-effective
strategy at 7 years. Continued analysis of IDE data should be performed to validate long-term cost-effectiveness of these
treatment strategies.
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Introduction
Anterior cervical discectomy and fusion (ACDF) has long
been considered the “gold standard” for treating degenera-
tive conditions of the cervical spine that are refractory to
conservative management.1-5 While outcomes following
ACDF are generally favorable, the technique restricts
cervical range of motion and may accelerate adjacent seg-
ment degeneration.6-8
Cervical disc replacement (CDR) was developed to mitigate
some of the negative aspects of ACDF, and as a motion-
preserving treatment modality it may be an effective
alternative.9,10 The increasing popularity of CDR has been
complemented by a number of Food and Drug Administration
(FDA) investigational device exemption (IDE) studies that
have demonstrated similar clinical outcomes between ACDF
and CDR for both 1- and 2-level procedures.11-18
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In the case of 2 competing treatment modalities, cost-
effectiveness analysis (CEA) can be an important tool for pro-
viding additional economic insight into the benefits of one
procedure over another.19 Current studies demonstrate CDR
to have lower costs than ACDF for 1- and 2-level procedures
in the short term, but few studies have established long-term
cost-effectiveness of CDR.20-22
The Prestige LP Cervical Disc (Medtronic Inc, Minneapolis,
MN) has superior clinical outcomes at 7-year follow-up com-
pared to ACDF for single-level procedures, but the cost-
effectiveness of this device at long-term follow-up (7 years)
for single-level procedures has yet to be determined.11,12 Our
objective with this study was to use 7-year follow-up data from
the single-level Prestige CDR IDE to conduct a cost-
effectiveness analysis comparing CDR to ACDF. Our results
will provide an economic perspective for making an informed
decision about which treatment modality to use for treating
degenerative conditions of the cervical spine.
Materials and Methods
Study Design
This CEA model followed the guidelines of the Panel on Cost-
Effectiveness in Health and Medicine.23 This panel established
a set of methodological guidelines that when followed provide
standardization and allow for the establishment of consistent
quality and comparable results. This study did not require insti-
tutional review board approval as all data obtained from the
original FDA IDE study was completely de-identified.
A Markov state-transition model was constructed using a
common decision-analysis software package (TreeAge Pro
2015; TreeAge Software, Williamstown, MA). A Markov
state-transition model allows for the direct comparison of the
relative costs and effectiveness of different treatment options.
The model was constructed from the payer perspective, in
which only the health care described in the catalog of reim-
bursed items is relevant and the reimbursement rates directly
reflect the costs of the model.
The primary effectiveness in this study was presented as
quality-adjusted life years (QALYs). Costs were expressed in
2014 dollars. All input variables in this model were discounted
at the standard rate of 3% to reflect present-day value. The
outcomes of the model were expressed as incremental cost-
effectiveness ratios (ICERs)($/QALY), which allow for the
comparison of the relative cost-effectiveness of 2 procedures.
Outcomes and transition-state probabilities were determined
from the data presented in the Medtronic Prestige Single-
Level CDR IDE study.
Model Structure
The conceptual structure of the Markov transition-state model
is demonstrated in Figure 1. The model represents the 2 treat-
ment strategies, CDR and ACDF, that can be used to treat
single-level cervical degenerative disc disease. Each surgical
strategy was represented by 5 discrete transition states: (1)
Well State, (2) Index Revision State, (3) Adjacent Segment
Revision State, (4) Complication State, and (5) Death State.
Transition probabilities between the various transition-
states were determined from the Medtronic Prestige Single-
Level IDE study (Table 1). These probabilities were
expressed as probability of occurrence/annum. Perioperative
death was assigned a value of zero as there were no perio-
perative mortalities in the IDE study and the risk of death
from anesthesia remains extremely low. Patients could only
enter into the complication for the first 90 days of the first
cycle to represent any perioperative complication risk. Simi-
larly, a 90-day complication window could also be entered
after index or adjacent segment revision.
Health state utility values were assigned to each of the
Markov transition states. The utility value represents the
value obtained by the patient for remaining in that health state
for one cycle.
A willingness-to-pay threshold of $50 000/QALY was
used. A probabilistic sensitivity analysis was performed using
a Monte Carlo simulation of 10 000 cycles to validate the
input variables in the model. Confidence intervals were
reported at 95%.
Utilities
Utility values can range from 0 to 1, with 0 representing death
and 1 representing perfect health. Overall, health state utilities
are a required part of any CEA analysis as they represent a
reliable measure of the health-related quality of life. When a
CEA model is run over a number of cycles, health state utilities
are combined with survival estimates and are aggregated across
the model to generate QALYs.
Short Form 36 (SF-36) data from the Single-Level Prestige
LP CDR IDE study for 1212 CDR patients and 183 ACDF
patients was used. The raw SF-36 data was collected at
baseline, 12 months, 24 months, 36 months, 60 months, and
84 months postoperatively. SF-36 data was converted into
health state utilities using the SF-6D algorithm, which is a
preference-based index obtained from a sample of the general
population using the recognized valuation technique of
standard gamble (Table 2).
Revision surgery at the index segment or adjacent segment
were assumed to have a utility similar to that of the base-case
state (preoperative state).
Costs
Gross cost methodology was used to estimate the direct costs of
both CDR and ACDF. International Classification of Diseases,
Ninth Revision, Diagnosis Related Group (DRG) and Current
Procedural Terminology (CPT) codes specific for each surgical
procedure were used. Combining the reimbursement rates for
each DRG and CPT using 2014 Medicare date, an accurate
representation of the direct costs could be obtained (Table 3).
To reflect the values of a private payer system, Medicare
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Figure 1. Visual representation of the Markov transition-state model. Each surgical treatment was associated with 5 distinct transition-states:
(1) Well State, (2) Index Revision State, (3) Adjacent Segment Revision State, (4) Complication State, and (5) Death State.
34 Global Spine Journal 8(1)
reimbursement rates were multiplied by 140%. All costs in this
study were denominated in 2014 dollars.
Sensitivity Analysis
As CEA models are built on advanced statistical decision and a
certain level of uncertainty exists with respect to parameters
and observable variables within the model, it is necessary to
perform a robust sensitivity analysis to validate the model. A
probabilistic sensitivity analysis (PSA) was used in our model,
which is a procedure by which all the input variables are
considered as random quantities and can be associated with a
probability distribution. A Monte Carlo simulation was used to
perform the PSA across 10000 discrete iterations.
Results
Base Case
The model was constructed to treat a 40-year-old patient with
single-level degenerative disc disease who had failed appropri-
ate conservative care and was an ideal surgical candidate for
CDR or ACDF.
Procedure-Related Costs
Costs were generated using a 140% multiple of 2014 Medicare
reimbursement for the associated DRG and CPT codes for each
procedure. All costs were discounted at 3% to represent
present-day value. The base case analysis generated a 7-year
cost of $172989 for CDR and $143714 for ACDF (Table 4).
ACDF resulted in a 7-year cost savings of $29275 when com-
pared with CDR.
Procedural Effectiveness
CDR resulted in a generation of 4.53 QALYs, while ACDF
resulted in 3.85 QALYs (Table 4). Over the 7 years represented
by the model, CDR resulted in a net gain of 0.67 QALYs when
compared with ACDF.
Procedural Cost-Effectiveness
CDR resulted in an increased incremental cost of $29275 with
an incremental gain of 0.67 QALYs when compared with
ACDF. The cost-effectiveness ratio of CDR was $38 247/
QALY, while ACDF was $37325/QALY. The ICER of CDR
was $43 522/QALY, which reached the willingness to pay
(WTP) threshold of $50000/QALY (Table 3).
Probabilistic Sensitivity Analysis
The results of the Monte Carlo simulation are demonstrated in
Table 5. Figure 2 represents the cost-effectiveness scatter plot
of the 10000 simulations comparing CDR and ACDF. Simula-
tions to the right of the WTP line represent those values in
which CDR is the more cost-effective strategy. Assuming a
WTP $50 000/QALY, the cost-effectiveness acceptability
curve indicated that CDR would be chosen 56% of the time
based on 10000 simulations (Figure 3).
Discussion
The objective with this study was to independently analyze
prospectively collected data with 7-year clinical follow-up
from the Prestige Cervical Disc Investigational Device Exemp-
tion Study. A number of FDA IDE studies comparing both 1-
level and 2-level CDR to ACDF have demonstrated similar
Table 1. Transition Probabilities Used in the Model.
Event Cycle Probability
ACDF complication 0.11
ACDF index revision 0.05
ACDF adjacent revision 0.044
CDR complication 0.081
CDR index revision 0.017
CDR adjacent revision 0.02
Mortality CDC life tables
Abbreviations: ACDF, anterior cervical discectomy and fusion; CDR, cervical
disc replacement; CDC, Centers for Disease Control and Prevention.
Table 2. Utility Scores at Each Time Point as Derived From the SF-6D.







Abbreviations: CDR, cervical disc replacement; ACDF, anterior cervical dis-
cectomy and fusion.
Table 3. Costs in 2014 Dollars for Selected CPT and DRG Codes.
Code Cost ($) Code Cost ($)
Single-level CDR 84.62 17965 22856 1791.22
CDR complication 8068.12





Revision CDR 84.66 17965 22861 2262.21
22864 2034.74





Abbreviations: CPT, Current Procedural Terminology; DRG, Diagnosis
Related Group; CDR, cervical disc replacement; ACDF, anterior cervical dis-
cectomy and fusion.
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clinical outcomes between the 2 treatment modalities.11-17
Cost-effectiveness analyses have also suggested CDR to be a
more cost-effective alternative than ACDF out to 5 years, but
the cost-effectiveness has yet to be assessed at 7 years post-
treatment.20-22
This study utilized a Markov-state transition model with a
robust probabilistic sensitivity analysis to assess the relative
cost-effectiveness of single-level CDR versus ACDF at 7 years.
A Markov model allows for effective modeling of the deci-
sions, outcomes, and associated cost involved in medical deci-
sion making. The transition state model allows for a patient to
travel between various health states over time based on the real-
world probability of doing so. Markov modeling of health care
decision making is a well-validated technique and has been
applied widely within orthopedics and increasingly within the
realm of spine surgery. This study is one of the first to utilize
the technique of Monte Carlo simulations as a means of
performing a robust sensitivity analysis to validate the input
variables used as part of the model.
The utility values in our model were derived from the SF-36
data from the Prestige IDE trial comparing outcomes of CDR
and ACDF. SF-36 was the chosen metric as it is a validated
means of translating these scores into a quantitative health
utility value for use in CE modeling.24,25 SF-36 data was con-
verted into health state utilities using the SF-6D algorithm,
which is a preference-based index obtained from a sample of
the general population using the recognized valuation tech-
nique of standard gamble.
The results of this Markov simulation demonstrated that
CDR was a more cost-effective option at 7 years when com-
pared with ACDF. While both strategies can be considered
cost-effective options with CE ratios less than $50 000/
QALY, the ICER when comparing CDR and ACDF was
found to favor CDR. Furthermore, while CDR was shown to
be incrementally more expensive than ACDF, there was a
significant gain in QALYs when compared with ACDF. The
results of this analysis are further supported by the results of
the PSA. The input variables were validated as accurate when
analyzed across 10 000 simulations. Furthermore, CDR was
found to be the more cost-effective option 56% of the time.
The use of PSA analysis provides a more robust validation
of the input variable. Historically, CEA studies have utilized
1- and 2-way sensitivity analyses to validate variables of
interests. These types of analyses are considered deterministic
and fail to consider the possible correlation or the underlying
uncertainty about the variable of interest, focusing instead on
a set of arbitrarily chosen values. PSA consider all of the input
variables as random quantities with an assigned probability
distribution to them.
Our results demonstrate the cost benefits of CDR, and the
literature suggests clinical benefits as well. Burkus et al inde-
pendently analyzed single-level 7-year clinical and radio-
graphic outcome data from the Prestige Cervical Disc IDE.11
The authors found that the overall success rate was 6.4%
greater in the CDR group at 5 years, though this was not sta-
tistically significant. The overall success at 7 years, however,
was 12.6% greater in the CDR group and was statistically
significant, suggesting long-term clinical success of CDR and
underscoring the importance of long-term follow-up. The
authors defined overall success by 5 criteria; postoperative
neck disability index score improvement of at least 15 points
from preoperative, maintenance or improvement in neurologic
status, functional spinal unit (FSU) disc height maintenance, no
serious adverse event, and no additional surgical procedure.
When examining individual clinical and radiographic out-
comes, the authors observed a statistically significant lower
Table 4. Base Case Cost-Effectiveness Rankings of One-Level ACDF Versus CDR.
Strategy Cost ($) Incremental Cost Effectiveness (QALY) Incremental Effectiveness ICER ($/QALY) Cost-Effectiveness
ADCF 143714 3.85 37325
CDR 172989 29275 4.53 0.67 43522 38247
Abbreviations: ACDF, anterior cervical discectomy and fusion; CDR, cervical disc replacement; QALY, quality adjusted life year; ICER, incremental cost-
effectiveness ratios.
Table 5. Results of the Monte Carlo Probabilistic Sensitivity Analysis
of 10 000 Case Simulations.
























Size (n) 10000.00 10000.00
Abbreviations: CDR, cervical disc replacement; ACDF, anterior cervical
discectomy and fusion.
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mean neck pain score of 4.2, higher mean SF-36 score of 1.9,
and greater neurologic success in the CDR group compared to
the ACDF group. The authors suggest the greater neurologic
success in the CDR group may have been attributed to a larger
posterior decompression that occurred during CDR. There
were no statistical differences between the groups with regard
to arm pain, FSU failure, adjacent segment angular motion,
dysphagia, or implant removal. There were higher rates of
secondary surgery (4.8% vs 13.7%), revision surgery (0% vs
2.1%), supplemental fixation (0% vs 2.3%), and adjacent-level
Figure 2. Depiction of the cost-effectiveness scatter plot of 10000 simulations. Simulations to the right of the willingness to pay (WTP) line
indicate values where CDR is the more cost-effective option.
Figure 3. Based on 10000 simulations, the cost-effectiveness acceptability curve indicated CDR would be chosen 56% of the time, assuming a
WTP $50000/QALY.
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surgery in the ACDF group compared to the CDR group (4.6%
vs 11.9%), all of which were statistically significant. With
respect to adverse events, the CDR group had fewer spinal
events (20.9% vs 38.9%), but more urogenital events (20.1%
vs 12.2%), than the ACDF group, and also had a higher inci-
dence of broken screws (5 cases vs 0 cases) than the ACDF
group. All of these adverse event findings were statistically
significant. These results suggest several advantages of CDR
compared to ACDF with respect to clinical outcomes and addi-
tional required surgeries.11 A second clinical and radiographic
study of the 7-year Prestige cervical data by Gornet et al cor-
roborated these findings.26
Different types of cost-effectiveness analyses have shown
CDR to be a more cost-effective option than ACDF.20,21,27,28
Ament et al compared cost-utility of CDR and ACDF for
2-level procedures using 5-year follow-up data.20 They used
the ICER to calculate the cost-utility outcome, and a value
under the commonly accepted threshold of $50 000 WTP
would favor CDR. The authors used a Markov model to ana-
lyze costs and health utility outcomes. While CDR was asso-
ciated with a greater cost of $1687 than ACDF over 5 years, it
was also associated with less productivity loss of $34377 over
3 years. The authors postulate the reduced productivity loss of
CDR compared to ACDF was due to earlier return to work in
the CDR group. The CDR cohort had 3.57 QALYs compared to
3.38 QALYs in the ACDF cohort. Incorporating the productiv-
ity loss, the authors suggest that CDR dominates ACDF from a
cost utility perspective at 5 years. We found similar results in
that despite initial greater cost of CDR, incremental improve-
ment in QALYs in the CDR cohort suggest its effectiveness
over ACDF. These types of cost-effectiveness analyses offer an
economic perspective that may help inform decision-making
when considering 2 treatment options.
This study has several limitations that are worth noting. Our
model assumes a definite number of potential outcomes states,
for which a patient may only enter once. For example, a patient
may only enter into a revision state once, which may understate
the possibility of requiring further revision surgery. Addition-
ally, the use of a transition state model may undersimplify the
real-world health transitions that a patient can make as part of
their postoperative course. The cycle length was set to 1 year in
this model. It is important to note that in real life a patient is not
bound to cycle length and may in fact transition between health
states more frequently than what is able to be accurately mod-
eled with a decision analysis.
Another potential limitation of this study is the use of only
direct costs in the model. The authors utilized gross-costing
techniques based off of the payer perspective. Indirect costs
including return to work data were not included in this study.
Indirect costs require the use of micro-costing techniques,
which have been shown to be cumbersome and difficult to
accurately collect. Furthermore, the use of gross-costing has
been repeatedly shown by health care economist to be a more
plausible economic measure for routine use.
This study provides a validated model of the relative cost-
effectiveness of single-level CDR and ACDF at 7 years. There
remains uncertainty surrounding the potential long-term survi-
vability of the CDR implant. Though this study represents one
of the first to present data out to 7 years, its remains possible
that CDR implant failure can occur at a later date. Continued
surveillance of the IDE studies with long-term follow-up is
necessary to validate the findings in this model.
Conclusion
One-level CDR and ACDF are both cost-effective strategies for
the treatment of single-level degenerative disc disease at
7 years. The results of this model indicate, however, that CDR
is the more cost-effective strategy with an ICER less than
$50000/QALY. The results of this Markov simulation were
strongly supported with the use of a Monte Carlo simulation
of 10 000 cycles. Further surveillance of the IDE studies is
required to validate the long-term validity of this model.
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